

11 November 2020

Dear Healthcare Professional,

**NOTIFICATION OF TEMPORARY ALTERNATIVE PRODUCT SUPPLY**

Status	Presentation	Registration Number	Pack Size	Stock Status
OUT OF STOCK	Pregabalin Pfizer 150 mg Capsules	TT50-7184d	Blister of 56's	Current
TEMPORARY ALTERNATIVE (Australian-Product)	Lyrica (pregabalin) 150 mg Capsules	TT50-10845b	Blister of 56's	12 Nov 2020

All pharmacological aspects of the two products are identical and dosing instructions are the same. There are differences in carton labelling and patient information documents. This information is listed in the table below:

CATEGORY	NEW ZEALAND PRODUCT Pregabalin Pfizer 150 mg	AUSTRALIAN PRODUCT Lyrica 150 mg
Active Tablet Appearance	White hard gelatin capsule, marked 'Pfizer' on the cap and 'PGN 150' on the body with black ink.	White hard gelatin capsule, marked 'Pfizer' on the cap and 'PGN 150' on the body with black ink.
Sponsor Contact Details	Upjohn New Zealand ULC Auckland, New Zealand	Upjohn Australia Pty Ltd Sydney, NSW, Australia
Medical Information	New Zealand: 0800 736 363 <a href="mailto:medicalaffairs.anz@pfizer.com">medicalaffairs.anz@pfizer.com</a>	Australia: 1800 675 229 <a href="mailto:medicalaffairs.anz@pfizer.com">medicalaffairs.anz@pfizer.com</a>
Poisons Contact Details	National Poisons Centre (Telephone 0800 764 766)	Poisons Information Centre (Telephone 13 11 26)

Please refer to the Pregabalin Pfizer Data Sheet and Consumer Medicines Information document at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) for complete product information. These documents are aligned with the Australian Product Information and Consumer Medicine Information.

We thank you in advance for your understanding and apologise for any inconvenience caused to you and your patients.

For any medical or stock queries please contact Upjohn New Zealand ULC on 0800 736 363. Please report any suspected adverse events via email to Pfizer Drug Safety at [AUS.AEReporting@pfizer.com](mailto:AUS.AEReporting@pfizer.com).

Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) in Dunedin online at <https://nzphvc.otago.ac.nz/reporting> or by email to [carmnz@otago.ac.nz](mailto:carmnz@otago.ac.nz).

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Kannan', written in a cursive style.

Dr Kannan Subramaniam  
Senior Medical Director  
Upjohn New Zealand